Finance Watch: Syndax Has A Standout Post-ASH Offering As Peers Scramble For Cash
Others Are Less Lucky, Opting To Cut Programs, Jobs
Public Company Edition: Syndax grossed $230m in a follow-on public offering based on positive results for its menin inhibitor in leukemia, but the FOPO was an outlier relative to other companies, which relied on private placements, debt and other options to raise cash in a tough market.
